Dr. Mahtani on the Use of CDK 4/6 Inhibitors in Metastatic ER+ Breast Cancer

Video

In Partnership With:

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the use of CDK 4/6 inhibitors in older patients with estrogen receptor-positive breast cancer.

Reshma L. Mahtani, DO, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the use of CDK 4/6 inhibitors in older patients with estrogen receptor-positive breast cancer.

An FDA pooled analysis of the registration trials that led to the approval of CDK 4/6 inhibitors was presented at the 2017 San Antonio Breast Cancers Symposium. In the analysis, investigators looked at the studies with respect to age and treatment effect. Although CDK 4/6 inhibitors are very efficacious and pretty well tolerated, physicians wondered whether older patients could tolerate the medication as well as younger patients.

The use of CDK 4/6 inhibitors is something that should be considered in older patients, says Mahtani. Age should not be used as a reason not to administer these agents. Although there was an increased incidence of treatment discontinuation and increased grade 3/4 toxicity, the differences in select adverse events that are associated with the use of these therapies were not that great.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD